TBTayibe Bal

Tayibe Bal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tayibe Bal has a total of 287 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Direct-Acting Antivirals in Patients with Hepatitis C Infection: Nationwide Real-life Data from Türkiye

    by Alper Gunduz, Nefise Çuvalcı Öztoprak, Nagehan Didem Sarı, Behice Kurtaran, Yusuf Önlen, Ebubekir Senates, Esra Zerdali, Hasan Karsen, Ayse Batırel, Rıdvan Kara Ali, et al.

    Background/Aims: Chronic hepatitis C virus (HCV) infection constitutes a substantial healthcare concern in Türkiye. The clinical application of direct-acting antiviral medications (DAAs) has transformed its management. The goal is to assess the efficacy and safety of DAAs in the real-world setting in Turkish patients with chronic HCV. Materials and Methods: Thirty-seven centers from Türkiye recorded 1807 patients to the database. Patients aged >18 years were enrolled to the study. Their demographics, clinical information, DAAs used, efficacy, and safety information were evaluated. Efficacy and safety results were reported for patients with 12-week post-treatment (SVR12) data. Results: Among the patients, 919 (50.9%) were female with a mean of age 56 Å} 15 years (range:18-97 years) and 238 (13%) were cirrhotic. Liver biopsy was performed in 296 patients. Mean histologic activity index score was 7.68 and fibrosis score was 2.58. Baseline mean viral load was 4.11Å~106 copies/mL. Patients received the following treatments: Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir (PrOD):706, Ledipasvir+Sofosbuvir:490, Sofosbuvir+Ribavirin:176, PrOD+Ribavirin:175, Ledipasvir+Sofosbuvir+Ribavirin:156, PrO+Ribavirin:32, and PrO:10. Response at the end of treatment was 99.2% (1454/1465) and SVR12 was 97.8% (1289/1318). The DAAs were generally well tolerated. Ten and 13 patients discontinued therapy because of drug-related and unrelated adverse side effects, respectively. Conclusion: This real-world study demonstrated that DAA treatment for HCV is both safe and highly effective. In two-thirds of the patients, the hepatic inflammation is moderate to severe, and fibrosis is moderate to advanced in half of them. Patients’ characteristics suggest that HCV infection is often not diagnosed or treated until patients present with moderate-to-severe stage, indicating that diagnostic and therapeutic approaches should be used more effectively. Cite this article as: Gunduz A, .ztoprak N., Sarı ND, et al. Efficacy and safety of direct-acting antivirals in patients with hepatitis Cinfection: nationwide real-life data from Türkiye. Turk J Gastroenterol. Published online April 10, 2026. doi:10.5152/tjg.2026.25287

  • Open Access

    A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate

    by Tansu Yamazhan, Esra Zerdali, Yusuf Önlen, Selma Tosun, Özgür Günal, Ayşe Batırel, İmran Hasanoğlu, Tuba Turunç, Umay Balcı, Sibel Yıldız Kaya, et al.

    Background/Aims: Selecting the initial antiviral regimen for chronic hepatitis B (CHB) requires balancing patients’ comorbidities and long-term safety. This study examines differences in patient and disease-related factors that guide clinicians to prescribe either ente cavir (ETV) or tenofovir disoproxil fumarate (TDF) as the initial treatment. Materials and Methods: The study included treatment-naïve CHB patients aged 18 or older who had been diagnosed for at least 1 year since 2010 and initiated on antiviral therapy. The data included variables such as age, gender, body mass index (BMI), comorbidities, liver disease activity, biopsy results, cirrhosis, hepatic steatosis, hepatitis B e-antigen status, hepatitis B virus DNA levels, triglycerides, cholesterol, renal function, and baseline bone mineral density (BMD), which were assessed by dual-energy x-ray absorptiometry (DEXA). Results: Among 2259 patients (61.6% male), 1270 patients (56.22%) received TDF, while 989 patients (43.78%) received ETV as firstline therapy. The TDF was more commonly prescribed to patients with a lower BMI (median

  • Open Access

    Multiple cranial tuberculomas with meningitis and miliary tuberculosis in an immunocompetent adult

    by Ahmet Doğan, Hasan Tahsin Gözdaş, Tayibe Bal, Sultan Beste Şahin

    Miliary brain tuberculosis (TB) is a rare and highly lethal clinical form resulting from the extensive lymphohematogenous spread of Mycobacterium tuberculosis. Widespread brain involvement often suggests immunosuppression. However, cases have been reported in immunocompetent adults. Prognosis depends largely on prompt diagnosis and initiation of treatment. This case report presents an immunocompetent adult with miliary pulmonary TB diagnosed by bronchoalveolar lavage (BAL) fluid analysis and diffuse brain tuberculomas on brain magnetic resonance imaging (MRI).

  • Open Access

    Multiple cranial tuberculomas with meningitis and miliary tuberculosis in an immunocompetent adult

    by Ahmet Doğan, Hasan Tahsin Gözdaş, Tayibe Bal, Sultan Beste Şahin

    Miliary brain tuberculosis (TB) is a rare and highly lethal clinical form resulting from the extensive lymphohematogenous spread of Mycobacterium tuberculosis. Widespread brain involvement often suggests immunosuppression. However, cases have been reported in immunocompetent adults. Prognosis depends largely on prompt diagnosis and initiation of treatment. This case report presents an immunocompetent adult with miliary pulmonary TB diagnosed by bronchoalveolar lavage (BAL) fluid analysis and diffuse brain tuberculomas on brain magnetic resonance imaging (MRI).

  • Relationship of Semaphorin Proteins with Blood Markers in Patients with COVID-19

    by Hamza Malik Okuyan, Serdar Doğan, Tayibe Bal, Mehmet Çabalak

    Amaç: COVID salgını dünya çapında sosyo-ekonomik yaşamı ve sağlık sistemlerini etkileyen ciddi bir sağlık sorunudur. Semaforinlerin bazı hastalıklardaki rolü nispeten bilinmesine rağmen, bu moleküllerin COVID-19'un patogenezi ile ilişkisi belirsizliğini koruyor. Bu nedenle, Semaforinlerin (Sema3A, Sema4A, Sema4D ve Sema7A) biyokimyasal ve inflamatuar değişikliklerle ilişkisini ve COVID-19 hastalarında hastalık varlığını ve hastalık şiddetini öngörmedeki rollerini araştırmayı amaçladık. Gereç ve Yöntem: Bu çalışmaya toplam 144 COVID-19 hastası ve 20 sağlıklı birey dahil edildi. Serum Semaforinleri, Enzime bağlı İmmünosorbent Tahlili kullanılarak analiz edildi. Diğer laboratuvar parametreleri, rutin laboratuvar teknikleri kullanılarak ölçüldü. Bulgular: Sema3A konsantrasyonları, sağlıklı kontrollerle karşılaştırıldığında hem şiddetli hem de şiddetli olmayan COVID-19 grubundaki hastalarda yüksekti (p<0.0001). Şiddetli COVID-19 grubundaki hastalarda Sema4A seviyeleri anlamlı olarak azaldı (p=0.002). Sema3A, EOS, RBC, HGB, HCT ve MCV gibi rutin hematolojik belirteçlerle negatif korelasyon gösterdi. Ayrıca Sema3A, D-dimer ve fibrinojen gibi pıhtılaşma belirteçleri ve ESR, CRP, PCT ve ferritin gibi inflamatuar belirteçler ve ALT, AST, BUN, CK ve LDH gibi biyokimyasal belirteçler ile pozitif korelasyon göstermiştir. Sema4A, WBC ile negatif korelasyon gösterirken, LYM ve HCT ile pozitif korelasyon gösterdi. 3,03 ng/mL'nin üzerindeki Sema3A seviyeleri ve 11,8ng/mL'nin altındaki Sema4A konsantrasyonları COVID-19'un varlığını öngörebilir (sırasıyla p<0,0001, p=0,02). Sonuç: Burada sunulan verilerimiz, Sema3A ve Sema4A'nın COVID-19 için tanısal belirteçler olabileceğini ve hastalığın klinik yönetiminde önemi olabileceğini düşündürmektedir.

  • Comparison of Patients with and without Coronavirus-19 Infection in Terms of Acquired Immune Response to Hepatitis A: A Retrospective Study

    by Tayibe Bal, Hasibullah Yaqoobi̇, Yusuf Önlen, Mehmet Çabalak, Serdar Doğan

    This study aimed to examine whether there is a difference in the level of immune response against hepatitis A virus between patients with and without COVID-19 infection. Fifty patients with COVID-19 disease (confirmed by PCR positivity) who were followed in our clinic between 1 June 2020 and 1 September 2020 were enrolled in this cross-sectional, retrospective, single-center study. A total of 150 patients, who had similar demographic characteristics and were randomly selected among the patients who Anti HAV IgG levels were determined during their admission to our clinic in the last two years before the pandemic (November 1, 2017-November 1, 2019) were taken as the control group. Anti-HAV IgG seropositivity rates and serum antibody titers were compared between these two groups. The median age of the 200 cases was 48.5 (25.-75. Quartiles=43.0-59.0) years, 108 (54%) were male and 92 (46%) were female. One hundred, and forty-two of the cases were 60 years and above, but the proportion of the patients aged 60 and over in the patient groups was similar (p=0.105). Although anti-HAV IgG seropositivity rates in COVID-19 patients were similar to cases in the control group (p=0.062), anti-HAV IgG titers in COVID-19 cases were found to be significantly lower than in control patients (p<0.001). Anti-HAV IgG titers were found to be significantly lower in critical COVID-19 patients (n=7) compared to other COVID-19 patients (n=43, p=0.049)(Fig 2). In addition, it was observed that there was a significant and strong correlation between the anti-HAV IgG titer and the presence of critical COVID-19 disease (η=0.988). Although our results seem to support the thesis that the presence of HAV vaccine or previous HAV infection may be protective against COVID-19 infection, especially in terms of preventing critical disease course, prospective studies with larger patient series are needed to confirm these results. Bu çalışma ile COVID-19 enfeksiyonu olan ve olmayan olgular arasında Hepatit A virüsüne karşı kazanılmış immün yanıt düzeyi açısından fark bulunup bulunmadığının irdelenmesi amaçlanmaktadır. Bu retrospektif, kesitsel, tek merkez çalışmasına kliniğimizde 1 Haziran 2020-1 Eylül 2020 tarihleri arasında COVID-19 hastalığı (PCR pozitifliği ile doğrulanmış) nedeniyle takip edilmiş 50 olgu dahil edildi. Benzer demografik özelliklere sahip olan, salgın öncesindeki son iki yılda (1 Kasım 2017–1 Kasım 2019) kliniğimize başvuruları sırasında Anti HAV IgG düzeyleri belirlenmiş olgular arasından rastlantısal olarak seçilen toplam 150 olgu ise kontrol grubu olarak alındı. Bu iki grup arasında Anti-HAV IgG seropozitiflik oranları ile serum antikor titreleri karşılaştırıldı. Çalışmaya dahil edilen toplam 200 olgunun ortanca yaşı 48.5 (IQR=43.0-59.0) yıl olup, 108’i (%54) erkek, 92’si (%46) kadındı. Olguların 142’si (%71) 60 yaş ve üzerinde idi, ancak hasta grupları içerisindeki 60 yaş ve üzeri olguların oranı benzerdi (p=0.105). COVID-19 olgularındaki Anti-HAV IgG seropozitifliği oranları kontrol grubundaki olgularla benzer olmakla birlikte (p=0.062), COVID-19 olgularındaki anti HAV IgG titrelerinin, kontrol olgularındakine göre anlamlı oranda daha düşük olduğu görüldü (p<0.001). Anti-HAV IgG titrelerinin kritik seyirli COVID-19 olgularında (n=7), diğer COVID-19 olgularına (n=43) göre anlamlı oranda daha düşük olduğu görüldü (p=0.049)(Şekil 2). Buna ek olarak anti-HAV titresi ile kritik COVID-19 hastalığı varlığı arasında anlamlı ve güçlü düzeyde bir ilişki olduğu (η=0.988) görüldü. Sonuçlarımız HAV aşısı veya geçirilmiş HAV enfeksiyonu varlığının COVID-19 enfeksiyonunda, özellikle kritik hastalık seyrinin önlenmesi açısından, koruyucu olabileceği tezini destekliyor gibi görünse de bu sonuçların doğrulanabilmesi için daha geniş hasta serilerinde yapılacak prospektif çalışmalara ihtiyaç vardır.